Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Mayer J, Brümmendorf TH, La Rosée P, Heim D, Krause SW, le Coutre PJB (2023) Treatment free remission after nilotinib plus peg-interferon alpha induction and peg-interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients; the Tiger trial. Blood 142(Supplement 1):446. https://doi.org/10.1182/blood-2023-182792

Article  Google Scholar 

Cortes J, Lang F (2021) Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol 14(1):44. https://doi.org/10.1186/s13045-021-01055-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manley PW, Barys L, Cowan-Jacob SW (2020) The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res 98:106458. https://doi.org/10.1016/j.leukres.2020.106458

Article  CAS  PubMed  Google Scholar 

Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF, Fu Y, Sy SKB, Obourn V, Chakraborty A, Hourcade-Potelleret F (2024) Clinical pharmacology of asciminib: a review. Clin Pharmacokinet 63(11):1513–1528. https://doi.org/10.1007/s40262-024-01428-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, Garcia-Gutierrez V, Kapoor S, Allepuz A, Quenet S, Bedoucha V, Mauro MJ (2023) Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37(3):617–626. https://doi.org/10.1038/s41375-023-01829-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP, for the ASC4FIRST Investigators (2024) Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med 391(10):885–898. https://doi.org/10.1056/NEJMoa2400858

Article  CAS  PubMed  Google Scholar 

Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bedoucha V, Hochhaus A (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138(21):2031–2041. https://doi.org/10.1182/blood.2020009984

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gomez-Garcia de Soria V, le Coutre P, Mahon FX, Janssen J, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F (2023) Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior tkis: 4-year phase 1 safety and efficacy results. Leukemia 37(5):1048–1059. https://doi.org/10.1038/s41375-023-01860-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY (2022) Population pharmacokinetics of asciminib in tyrosine kinase inhibitor-treated patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic and acute phases. Clin Pharmacokinet 61(10):1393–1403. https://doi.org/10.1007/s40262-022-01148-9

Article  CAS  PubMed  Google Scholar 

Darstein C, Yoon D, Yang Y, Kapoor S, Dasgupta K, Wu S, Kawakita Y, Hoch M, Grosch K, Sy SKB (2025) Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 95(1):39. https://doi.org/10.1007/s00280-025-04755-y

Article  CAS  PubMed  Google Scholar 

Sy SKB, Yoon DY, Darstein C, Yang Y, Dasgupta K, Kapoor S, Hoch M, Grosch K (2025) Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model. Br J Clin Pharmacol 91(5):1419–1430. https://doi.org/10.1111/bcp.16381

Article  CAS  PubMed  Google Scholar 

Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, for the International Randomised Study of Interferon versus STI571 (IRIS) Study Group (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423–1432. https://doi.org/10.1056/NEJMoa030513

Article  CAS  PubMed  Google Scholar 

Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB (2022) Exposure-efficacy analysis of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther 112(5):1040–1050. https://doi.org/10.1002/cpt.2699

Article  CAS  PubMed  Google Scholar 

Rea D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D’Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A (2023) Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia 37(5):1060–1067. https://doi.org/10.1038/s41375-023-01888-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoch M, Bebrevska L, Singh N, Hourcade-Potelleret F (2023) Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants. Clin Pharmacol Drug Dev 12(5):484–492. https://doi.org/10.1002/cpdd.1213

Article  CAS  PubMed  Google Scholar 

Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, Hoch M, Ho YY (2024) Dose justification for asciminib in patients with Philadelphia chromosome-positive chronic myeloid leukemia with and without the T315I mutation. Clin Pharmacokinet 63(9):1301–1312. https://doi.org/10.1007/s40262-024-01411-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pamuk GE, Chow ECY, Ionan AC, Chen H, Lee SL, Hsu V, Grimstein M, Zheng N, Sun J, Charlab R, Gehrke BJ, Vallejo J, Ehrlich LA, de Claro RA, Theoret MR (2024) FDA approval summary: asciminib for Ph + CML in chronic phase treated with two or more tyrosine kinase inhibitors and for the T315I mutation. Clin Cancer Res 30(19):4266–4271. https://doi.org/10.1158/1078-0432.CCR-24-1086

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen J, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381(24):2315–2326. https://doi.org/10.1056/NEJMoa1902328

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on Imatinib. J Clin Oncol 28(14):2381–2388. https://doi.org/10.1200/JCO.2009.26.3087

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main reason for loss of CCyR and Imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733–3736. https://doi.org/10.1182/blood-2010-10-309807

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim Y, Go TH, Jang J, Lee JB, Lim ST, Shim KY, Lee JI, Kong JH (2021) Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia. Korean J Intern Med 36(6):1450–1458. https://doi.org/10.3904/kjim.2021.158

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen TC, Chen LC, Huang YB, Chang CS (2014) Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan. Int J Clin Pharm 36(1):172–181. https://doi.org/10.1007/s11096-013-9876-7

Article  CAS  PubMed  Google Scholar 

Efficace F, Vignetti M, Sparano F, Scalzulli E, Breccia M (2021) Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Expert Rev Hematol 14(3):293–302. https://doi.org/10.1080/17474086.2021.1886918

Article